US 11,858,942 B2
Triazolotriazine derivatives as A2A receptor antagonists
Sanxing Sun, Zhejiang (CN); Jinqi Ye, Zhejiang (CN); Long Zhao, Zhejiang (CN); Chongbo Hu, Zhejiang (CN); and Zhengshu Chen, Zhejiang (CN)
Assigned to ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD., Zhejiang (CN)
Appl. No. 17/255,451
Filed by ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD., Zhejiang (CN)
PCT Filed Jun. 26, 2018, PCT No. PCT/IB2018/054690
§ 371(c)(1), (2) Date Dec. 23, 2020,
PCT Pub. No. WO2020/002968, PCT Pub. Date Jan. 2, 2020.
Prior Publication US 2021/0292334 A1, Sep. 23, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 519/00 (2006.01); A61P 35/00 (2006.01); A61K 31/53 (2006.01); C07D 487/04 (2006.01)
CPC C07D 487/04 (2013.01) 3 Claims
 
1. A compound of formula (1):

OG Complex Work Unit Chemistry
wherein:
R is hydrogen;
Ar1 is 2-furanyl;
Ar2 is phenyl or pyridyl; and
Q is a 5-6 membered aromatic ring that is optionally substituted with X; X is optionally substituted C1-3 alkyl; any of said optionally substituted alkyl groups is substituted by halogen, cyano, methoxy, aryl, or heteroaryl,
or a pharmaceutically acceptable solvate or salt thereof.